{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T09:36:15Z","timestamp":1790674575157,"version":"4.1.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bbcan.2017.10.007","type":"journal-article","created":{"date-parts":[[2017,11,7]],"date-time":"2017-11-07T08:45:21Z","timestamp":1510044321000},"page":"78-84","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":187,"title":["Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1\/PD-L1 agents"],"prefix":"10.1016","volume":"1869","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-6173","authenticated-orcid":false,"given":"Matteo","family":"Santoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2745-8607","authenticated-orcid":false,"given":"Emanuela","family":"Romagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziana","family":"Saladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Foghini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Guarino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Capponi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Giannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo Decembrini","family":"Cognigni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Ferrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Battelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbcan.2017.10.007_bb0005","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Cancer Genome Atlas Network","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0010","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12032-008-9131-6","article-title":"Basal vs. luminal A breast cancer subtypes: a matched case-control study using estrogen receptor, progesterone receptor, and HER-2 as surrogate markers","volume":"26","author":"Ibrahim","year":"2009","journal-title":"Med. Oncol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0015","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ctrv.2016.12.010","article-title":"Targeting epidermal growth factor receptor in triple negative breast cancer: new discoveries and practical insights for drug development","volume":"53","author":"Costa","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0020","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1016\/S0140-6736(16)32454-0","article-title":"Molecular alterations in triple-negative breast cancer\u2013the road to new treatment strategies","volume":"389","author":"Denkert","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.21147\/j.issn.1000-9604.2017.03.10","article-title":"Role of tumor microenvironment in triple-negative breast cancer and its prognostic significance","volume":"29","author":"Yu","year":"2017","journal-title":"Chin. J. Cancer Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0030","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1464-410X.1989.tb05147.x","article-title":"Unexplained spontaneous regression and alpha-interferon as treatment for metastatic renal carcinoma","volume":"63","author":"Oliver","year":"1989","journal-title":"Br. J. Urol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0035","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/S0022-5347(17)36874-X","article-title":"Spontaneous regression of histologically proved pulmonary metastases from renal cell carcinoma: a case with 5-year follow-up","volume":"148","author":"Vogelzang","year":"1992","journal-title":"J. Urol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0040","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s10555-012-9415-3","article-title":"Stromal cells in tumor microenvironment and breast cancer","volume":"32","author":"Mao","year":"2013","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cell.2010.03.014","article-title":"Macrophage diversity enhances tumor progression and metastasis","volume":"141","author":"Qian","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0050","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1189\/jlb.0609385","article-title":"Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation","volume":"86","author":"Solinas","year":"2009","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/19420862.2015.1011450","article-title":"Macrophages are critical effectors of antibody therapies for cancer","volume":"7","author":"Weiskopf","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0060","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0065","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0070","article-title":"PD-L1 and intratumoral immune response in breast cancer","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1186\/s12885-015-1204-2","article-title":"Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients","volume":"15","author":"Pistelli","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0085","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13058-015-0621-0","article-title":"Human breast cancer cells educate macrophages toward the M2 activation status","volume":"17","author":"Sousa","year":"2015","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0090","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1387\/ijdb.113371dl","article-title":"Tumor-associated macrophages in breast cancer: distinct subsets, distinct functions","volume":"55","author":"Laoui","year":"2011","journal-title":"Int. J. Dev. Biol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0095","article-title":"G-CSF regulates macrophage phenotype and associates with poor overall survival in human triple-negative breast cancer","volume":"5","author":"Hollm\u00e9n","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0100","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/1471-2407-12-306","article-title":"The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients","volume":"12","author":"Medrek","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2017.09.001","article-title":"Tumor associated macrophages are strongly related to vascular invasion, non-luminal subtypes and interval breast cancer","author":"Klingen","year":"2017","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0110","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1111\/cas.13287","article-title":"High density of CD204-positive macrophages predicts worse clinical prognosis in patients with breast cancer","volume":"108","author":"Miyasato","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0115","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2016.11.003","article-title":"Activation of GPER suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-kB\/IL-6 signals","volume":"386","author":"Liang","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0120","doi-asserted-by":"crossref","first-page":"24495","DOI":"10.18632\/oncotarget.8336","article-title":"Adipose microenvironment promotes triple negative breast cancer cell invasiveness and dissemination by producing CCL5","volume":"7","author":"D'Esposito","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0125","doi-asserted-by":"crossref","first-page":"115","DOI":"10.12659\/MSM.895386","article-title":"Expression of tumor-related macrophages and cytokines after surgery of triple-negative breast cancer patients and its implications","volume":"22","author":"Wang","year":"2016","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0130","doi-asserted-by":"crossref","first-page":"9188","DOI":"10.1038\/srep09188","article-title":"Characterization of macrophage - cancer cell crosstalk in estrogen receptor positive and triple negative breast cancer","volume":"5","author":"Hollm\u00e9n","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0135","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbrc.2011.06.102","article-title":"Breast cancer subtypes express distinct receptor repertoires for tumor-associated macrophage derived cytokines","volume":"411","author":"Levano","year":"2011","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0140","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00262-014-1519-x","article-title":"PD-1(+) immune cell infiltration inversely correlates with survival of operable breast cancer patients","volume":"63","author":"Sun","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0145","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal4922","article-title":"Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer","volume":"9","author":"Nolan","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0150","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0155","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1093\/annonc\/mdv192","article-title":"PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes","volume":"26","author":"Ali","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0160","article-title":"PD-L1 and survival in solid tumors: a meta-analysis","volume":"10","author":"Wu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0165","doi-asserted-by":"crossref","first-page":"26483","DOI":"10.18632\/oncotarget.4494","article-title":"Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer","volume":"6","author":"Barrett","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0170","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","article-title":"PD-L1 expression in triple-negative breast cancer","volume":"2","author":"Mittendorf","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0175","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1158\/1078-0432.CCR-15-1125","article-title":"RAS\/MAPK activation is associated with reduced tumor-infiltrating lymphocytes in triple-negative breast cancer: therapeutic cooperation between MEK and PD-1\/PD-L1 immune checkpoint inhibitors","volume":"22","author":"Loi","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0180","doi-asserted-by":"crossref","first-page":"24706","DOI":"10.18632\/oncotarget.14960","article-title":"Cancer-associated oxidoreductase ERO1-\u03b1 promotes immune escape through up-regulation of PD-L1 in human breast cancer","volume":"8","author":"Tanaka","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","article-title":"Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer","volume":"146","author":"Muenst","year":"2014","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0190","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.18632\/oncotarget.3216","article-title":"Prognostic and predictive value of PDL1 expression in breast cancer","volume":"6","author":"Sabatier","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0195","doi-asserted-by":"crossref","first-page":"784","DOI":"10.7150\/jca.14549","article-title":"PD-L1 expression is associated with tumor FOXP3(+) regulatory T-cell infiltration of breast cancer and poor prognosis of patient","volume":"7","author":"Li","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0200","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.humpath.2015.09.006","article-title":"Prognostic significance of PD-L1 and PD-L2 in breast cancer","volume":"47","author":"Baptista","year":"2016","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0205","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.clbc.2015.07.006","article-title":"Prognostic implications of tumor-infiltrating lymphocytes in association with programmed death ligand 1 expression in early-stage breast cancer","volume":"16","author":"Park","year":"2016","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0210","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1093\/ajcp\/aqw134","article-title":"Stromal PD-L1 expression is associated with better disease-free survival in triple-negative breast cancer","volume":"146","author":"Li","year":"2016","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0220","doi-asserted-by":"crossref","first-page":"15584","DOI":"10.18632\/oncotarget.14698","article-title":"The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer","volume":"8","author":"Mori","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0225","doi-asserted-by":"crossref","first-page":"31347","DOI":"10.18632\/oncotarget.15532","article-title":"Expression of PD-L1 and prognosis in breast cancer: a meta-analysis","volume":"8","author":"Zhang","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0230","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/jclinpath-2016-203874","article-title":"Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1","volume":"70","author":"Joneja","year":"2017","journal-title":"J. Clin. Pathol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0235","doi-asserted-by":"crossref","DOI":"10.4161\/onci.23562","article-title":"Tumor-associated macrophages subvert T-cell function and correlate with reduced survival in clear cell renal cell carcinoma","volume":"2","author":"Dannenmann","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0240","first-page":"1843","article-title":"Role of tumor-associated macrophages in renal cell carcinoma","volume":"10","author":"Ikemoto","year":"2003","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0245","doi-asserted-by":"crossref","DOI":"10.1007\/s10147-017-1161-7","article-title":"PD-L1 induced by IFN-\u03b3 from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer","author":"Zhang","year":"2017","journal-title":"Int. J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.bbcan.2017.10.007_bb0250","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1172\/JCI91190","article-title":"IFN-\u03b3-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0255","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","article-title":"Transforming growth factor-beta and the immune response: implications for anticancer therapy","volume":"13","author":"Wrzesinski","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0260","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/nri2808","article-title":"The polarization of immune cells in the tumour environment by TGFbeta","volume":"10","author":"Flavell","year":"2010","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0265","first-page":"728","article-title":"Programmed cell death protein-1\/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role","volume":"4","author":"Santarpia","year":"2015","journal-title":"Transl. Lung Cancer Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0270","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1158\/0008-5472.CAN-12-4524-T","article-title":"Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8","volume":"73","author":"Hartman","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0275","doi-asserted-by":"crossref","DOI":"10.1111\/cas.13330","article-title":"Lack of IL-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy","author":"Ohno","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0280","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1189\/jlb.5RU0714-360RR","article-title":"Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP","volume":"97","author":"Fabbi","year":"2015","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0285","doi-asserted-by":"crossref","first-page":"59","DOI":"10.18388\/abp.2015_1153","article-title":"Interleukin 18 (IL-18) as a target for immune intervention","volume":"63","author":"Wawrocki","year":"2016","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0290","doi-asserted-by":"crossref","first-page":"32722","DOI":"10.18632\/oncotarget.16281","article-title":"Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0295","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/nrclinonc.2015.215","article-title":"Clinical relevance of host immunity in breast cancer: from TILs to the clinic","volume":"13","author":"Savas","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0300","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1016\/j.humpath.2013.03.010","article-title":"Metastatic triple-negative breast cancers at first relapse have fewer tumor-infiltrating lymphocytes than their matched primary breast tumors: a pilot study","volume":"44","author":"Cimino-Mathews","year":"2013","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0305","article-title":"The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC)","author":"Tomioka","year":"2017","journal-title":"Breast Cancer"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0310","article-title":"Tumor-infiltrating lymphocyte composition, organization and PD-1\/PD-L1 expression are linked in breast cancer","volume":"6","author":"Buisseret","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0315","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.imbio.2016.04.005","article-title":"Tim-3 identifies exhausted follicular helper T cells in breast cancer patients","volume":"221","author":"Zhu","year":"2016","journal-title":"Immunobiology"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0320","doi-asserted-by":"crossref","first-page":"33159","DOI":"10.18632\/oncotarget.16565","article-title":"Preferential accumulation of regulatory T cells with highly immunosuppressive characteristics in breast tumor microenvironment","volume":"8","author":"Syed Khaja","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0325","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s13058-014-0432-8","article-title":"Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration","volume":"16","author":"Liu","year":"2014","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0330","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/bjc.2012.524","article-title":"Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer","volume":"108","author":"West","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0340","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12865-016-0183-7","article-title":"Immune modulation of CD4+CD25+ regulatory T cells by zoledronic acid","volume":"17","author":"Liu","year":"2016","journal-title":"BMC Immunol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0345","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1161\/CIRCRESAHA.108.181040","article-title":"Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2","volume":"104","author":"Bae","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0350","doi-asserted-by":"crossref","first-page":"2795090","DOI":"10.1155\/2016\/2795090","article-title":"The reactive oxygen species in macrophage polarization: reflecting its dual role in progression and treatment of human diseases","volume":"2016","author":"Tan","year":"2016","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0355","doi-asserted-by":"crossref","first-page":"E761","DOI":"10.1073\/pnas.1620433114","article-title":"Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity","volume":"114","author":"Chamoto","year":"2017","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0360","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.4049\/jimmunol.1402180","article-title":"Programmed death-1 controls T cell survival by regulating oxidative metabolism","volume":"194","author":"Tkachev","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0365","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1056\/NEJMoa1200690","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0370","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","article-title":"Safety and activity of anti-PD-L1 antibody in patients with advanced cancer","volume":"366","author":"Brahmer","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0380","series-title":"AACR Annual Meeting. Abstract 2859","article-title":"Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer","author":"Emens","year":"2015"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0385","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.3892\/ijo.2016.3680","article-title":"CSF1 is involved in breast cancer progression through inducing monocyte differentiation and homing","volume":"49","author":"Ding","year":"2016","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0390","doi-asserted-by":"crossref","first-page":"49349","DOI":"10.18632\/oncotarget.9885","article-title":"Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment","volume":"7","author":"Fang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0395","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bone.2014.06.017","article-title":"CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems","volume":"66","author":"Liverani","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0400","first-page":"1735","article-title":"A new protein antidenaturant agent, bindarit, reduces secondary phase of adjuvant arthritis in rats","volume":"19","author":"Cioli","year":"1992","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0405","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s10585-012-9473-5","article-title":"Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models","volume":"29","author":"Zollo","year":"2012","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0410","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.1182\/blood-2008-12-172825","article-title":"Regulation of macrophage function in tumors: the multifaceted role of NF-\u03baB","volume":"113","author":"Hagemann","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0415","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1084\/jem.20080108","article-title":"\u201cRe-educating\u201d tumor-associated macrophages by targeting NF-kappaB","volume":"205","author":"Hagemann","year":"2008","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0420","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1158\/0008-5472.CAN-04-4262","article-title":"Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection","volume":"65","author":"Guiducci","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0425","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ccr.2010.11.009","article-title":"HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF","volume":"19","author":"Rolny","year":"2011","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0430","doi-asserted-by":"crossref","first-page":"10016","DOI":"10.18632\/oncotarget.3540","article-title":"Stat3 orchestrates interaction between endothelial and tumor cells and inhibition of Stat3 suppresses brain metastasis of breast cancer cells","volume":"6","author":"Lee","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0435","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1073\/pnas.1524668113","article-title":"Augmented efficacy of brentuximab vedotin combined with ruxolitinib and\/or Navitoclax in a murine model of human Hodgkin's lymphoma","volume":"113","author":"Ju","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.bbcan.2017.10.007_bb0440","first-page":"239","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"486","author":"Mace","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.bbcan.2017.10.007_bb0445","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bbrc.2017.02.128","article-title":"IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model","volume":"486","author":"Liu","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0450","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0455","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0460","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0465","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0470","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0475","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0480","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0485","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0490","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus everolimus in advanced renal-cell carcinoma","volume":"373","author":"Motzer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0495","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.ctrv.2016.06.002","article-title":"Economic sustainability of anti-PD-1 agents nivolumab and pembrolizumab in cancer patients: recent insights and future challenges","volume":"48","author":"Tartari","year":"2016","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0500","doi-asserted-by":"crossref","first-page":"501","DOI":"10.5858\/arpa.2015-0529-LE","article-title":"Testing PD-1\/PD-L1 expression in cancer therapy: pathologic insights and economic sustainability","volume":"140","author":"Montironi","year":"2016","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.bbcan.2017.10.007_bb0505","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2741\/2692","article-title":"Macrophage activation and polarization","volume":"13","author":"Martinez","year":"2008","journal-title":"Front. Biosci."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X17301841?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X17301841?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T06:29:42Z","timestamp":1603261782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X17301841"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0304419X17301841"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2017.10.007","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1\/PD-L1 agents","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2017.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}